Yahoo
Paris - Delayed Quote EUR

bioMérieux S.A. (BIM.PA)

90.50 +0.35 (+0.39%)
At close: October 30 at 5:35:07 PM GMT+1

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
Name Title Pay Exercised Year Born
Mr. Pierre Boulud
Chief Executive Officer 1.59M -- 1971
Mr. Guillaume Bouhours
Executive VP of Finance, Purchasing and Information Systems & CFO -- -- 1976
Aymeric Fichet
Head of Investor Relations -- -- --
Ms. Audrey Dauvet
Executive Vice President of Legal, Corporate Integrity & Public Affairs -- -- 1975
Ms. Valerie Leylde
Executive Vice President of Human Resources, Communications & CSR -- -- --
Mr. Pierre Charbonnier
Executive Vice President of Global Quality, Manufacturing & Supply Chain -- -- --
Mr. Yasha Mitrotti
Executive Vice President of Industrial Applications -- -- --
Mr. Frederic Beseme
Head of CSR 21.99k -- 1956
Ms. Jennifer Zinn
Executive Vice President of Clinical Operations -- -- --
Dr. Charles K. Cooper
Executive VP of Medical Affairs & Chief Medical Officer -- -- --

bioMérieux S.A.

376 Chemin De l’Orme
Marcy-l'Étoile, 69280
France
33 4 78 87 20 00 https://www.biomerieux.com
Sector: 
Healthcare
Full Time Employees: 
14,562

Description

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.

Corporate Governance

bioMérieux S.A.’s ISS Governance QualityScore as of October 1, 2026 is 7. The pillar scores are Audit: 4; Board: 6; Shareholder Rights: 9; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

June 9, 2026 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: